Navigation Links
CNIO team presents a new strategy to personalise cancer therapies
Date:4/29/2014

Tumour cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumour, even among those that are classified as part of the same type of tumours. This complexity, which researchers were not aware of just a few years ago, calls for new tools to filter relevant genetic information for the implementation and development of personalised therapies targeted at specific characteristics within each individual tumour.

Researchers led by Manuel Hidalgo, Vice-Director of Translational Research at CNIO, have developed a new strategy to personalised medicine in advanced cancer patients with a poor prognosis. The study has been published in the journal Clinical Cancer Research. Applying this new tool, the treatments induced clinical responses in up to 77% of patients, either through the stabilisation of their condition or through a partial clinical response.

During the first phase, the authors analysed the genetic signature of the tumours specifically, the hundreds of millions of letters that make up the exome; the part of the genome whose information produces proteins in 23 patients suffering from advanced cancers, such as pancreatic adenocarcinomas and colon cancer. By using whole exome sequencing and bioinformatics analyses, researchers picked out mutations that could play an important role in the growth and spread of tumours.

The second part of the study involved the use of Avatar mice to study potentially effective treatments according to the patient's genetic signature. As Elena Garralda, predoctoral researcher from Hidalgo's Group, points out, avatar mice are "one of the key aspects of our research."

AVATAR MICE: A TESTING GROUND FOR DRUGS

Avatar mice are used as a testing ground, with each patient having their own equivalent animal, in order to study the effectiveness of drugs under real conditions: if the drug works in the avatar, the likelihood of it also working in the patient is very high.

Therefore, the treatments that worked best in the avatar mice were the ones given to patients. The results showed clinical benefit, either the stabilisation of the disease or a partial clinical response, in up to 77% of patients.

"We have demonstrated that it is possible to apply our personalised cancer treatment strategy to the clinic", says Garralda, adding: "as we learn more about the genetic information obtained from cancer exome sequencing, future clinical trials will allow for the inclusion of patients with specific genetic alterations, and therefore a better access to cancer drugs."

FUTURE ASSAYS ON PANCREATIC CANCER

Currently, one the main objectives for the team is to study the efficiency of the procedures in a larger number of patients with advanced pancreatic cancer, thereby comparing them to standard treatments.

Pancreatic cancer often has a poor prognosis, with survival rates of less than 1 year. It is a complex and heterogeneous disease, meaning that the personalised study of the most relevant mutations in tumour growth (driver mutations) could be a promising strategy in the search for new treatments.


'/>"/>

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert  

Related biology news :

1. Report presents designs for study of cancer risks near US nuclear facilities
2. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
3. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
4. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
5. Crop Science Society of America presents 2012 class of fellows
6. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
7. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
8. July meeting presents animal and dairy science
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
11. Yin-yang effect of sodium and chloride presents salt conundrum
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CNIO team presents a new strategy to personalise cancer therapies
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... ... announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in ... analysis to isolate single cells and provide visual documentation of monoclonality for use ...
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass conversion ... and torrefied wood is the topic of a September 27 webinar ... economic viability of transportable biomass conversion facilities for producing biochar, briquettes, and torrefied ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces ... 2017 conference. , What: Digital Transformation in Medical Device – The Journey to ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... flexible scientist program (FSP)-- a flexible business approach similar to a full-time ... SSCI’s extensive project-based analytical and solid-state chemistry services and expertise with flexible ...
Breaking Biology Technology: